Phase 1/2, open-label, randomized study of the safety, efficacy and pharmacokinetics of Letrozole plus PD 0332991 (oral CDK 4/6 inhibitor) and Letrozole single agent for the first-line treatment of ER Positive, HER2 negative ADVANCED Breast

  • Rea, Daniel (Principal Investigator)
  • Stubbs, Clive (Co-Investigator)

Project Details

Short titlePhase 1/2, open-label, randomized study of the safety, efficacy and pharmacokinetics of Letrozole plus PD 0332991 (oral CDK 4/6 inhibitor) and Letrozole single agent for the first-line treatment of ER Positive, HER2 negative ADVANCED Breast
StatusFinished
Effective start/end date1/01/12 → 31/12/14

Funding

  • Sandwell & West Birmingham Hospitals